Title (en)

PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PROTEASOME INHIBITOR OR IMMUNOMODULATORY DRUG FOR THE TREATMENT OF HEMATOLOGICAL CANCER

Title (de)

PHARMAZEUTISCHE KOMBINATIONEN AUS EINEM HISTON-DEACETYLASE-HEMMER UND PROTEASOM-HEMMER ODER IMMUNOMODULATOR ZUR BEHANDLUNG VON BLUTKREBSERKRANKUNGEN

Title (fr)

COMBINAISONS PHARMACEUTIQUES D'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE ET D'INHIBITEUR DU PROTÉASOME OU DE MÉDICAMENT IMMUNOMODULATEUR POUR LE TRAITEMENT D'UN CANCER HÉMATOLOGIQUE

Publication

EP 3522891 A4 20200415 (EN)

Application

EP 17858740 A 20170929

Priority

- KR 20160127767 A 20161004
- KR 2017011015 W 20170929

Abstract (en)

[origin: WO2018066946A1] The present invention relates to a pharmaceutical combination for treating a hematological cancer comprising the histone deacetylase (HDAC) inhibitor of the chemical formula 1, a proteasome inhibitor or an immunomodulatory drug and a steroidal anti-cancer agent together.The pharmaceutical combination of the present invention can be useful for treating a hematological cancer such as multiple myeloma, by reducing toxicity which is the problem of the conventional HDAC inhibitor and exhibiting an equivalent level of pharmaceutical effects due to a complex inhibitory mechanism against the cancer of the compound of chemical formula 1 and its pharmaceutically acceptable salt, the proteasome inhibitor or the immunomodulatory drug and the steroidal anti-cancer agent.

IPC 8 full level

A61K 31/416 (2006.01); **A61K 31/454** (2006.01); **A61K 31/496** (2006.01); **A61K 31/56** (2006.01); **A61K 31/573** (2006.01); **A61K 31/69** (2006.01); **A61K 38/00** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP KR RU)

A61K 31/416 (2013.01 - KR); **A61K 31/454** (2013.01 - EP RU); **A61K 31/496** (2013.01 - EP KR RU); **A61K 31/56** (2013.01 - KR); **A61K 31/573** (2013.01 - EP KR RU); **A61K 31/69** (2013.01 - EP KR); **A61K 38/005** (2013.01 - EP); **A61K 38/05** (2013.01 - RU); **A61K 45/06** (2013.01 - RU); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - RU); A61K 2300/00 (2013.01 - KR)

Citation (search report)

- [I] JONATHAN L. KAUFMAN ET AL: "Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy", CLINICAL LYMPHOMA MYELOMA AND LEUKEMIA, vol. 13, no. 4, 17 June 2013 (2013-06-17), pages 370 - 376, XP055370013, ISSN: 2152-2650, DOI: 10.1016/j.clml.2013.03.016
- [A] CHANSU LEE ET AL: "Abstract 1695: CKD-581, a novel histone deacetylase inhibitor, synergistically enhances Bortezomib cytotoxicity in multiple myeloma cells", EXPERIMENTAL AND MOLECULAR THERAPEUTICS, 30 September 2014 (2014-09-30), pages 1695 - 1695, XP055673884, DOI: 10.1158/1538-7445.AM2014-1695
- [T] ANONYMOUS: "A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM) | Blood | American Society of Hematology", 13 November 2019 (2019-11-13), XP055674271, Retrieved from the Internet <URL:https://ashpublications.org/blood/article/134/Supplement_1/1847/427755/A-Phase-1-OpenLabel-MultiCenter-Study-of> [retrieved on 20200306]
- See references of WO 2018066946A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2018066946 A1 20180412; AU 2017338564 A1 20190502; AU 2017338564 B2 20200709; BR 112019006633 A2 20190702; CA 3038019 A1 20180412; CN 109789138 A 20190521; EP 3522891 A1 20190814; EP 3522891 A4 20200415; JP 2019529562 A 20191017; JP 2021020953 A 20210218; KR 102002581 B1 20190722; KR 20180037507 A 20180412; MX 2019003907 A 20190805; RU 2721409 C1 20200519; ZA 201902340 B 20200826

DOCDB simple family (application)

KR 2017011015 W 20170929; AU 2017338564 A 20170929; BR 112019006633 A 20170929; CA 3038019 A 20170929; CN 201780061019 A 20170929; EP 17858740 A 20170929; JP 2019537733 A 20170929; JP 2020180411 A 20201028; KR 20160127767 A 20161004; MX 2019003907 A 20170929; RU 2019108930 A 20170929; ZA 201902340 A 20190412